Katrina McCarten

The paper uses CRISPR base editing and structural analysis to identify functional residues in the PI3K pathway, revealing potential drug targets and allosteric pockets.

CRISPR-VUS identifies rare variants linked to gene dependency in cancer cell lines, prioritizing potential drivers and therapeutic targets through functional validation.

This study identifies on-target WRN mutations as resistance mechanisms in MSI cancer cells to WRN helicase inhibitors and suggests combination therapies to prevent resistance.